Miriam Freimer

Miriam Freimer's research focuses on neuromuscular disorders, especially myasthenia gravis, hereditary transthyretin amyloidosis with polyneuropathy, and inclusion body myositis. Much of the work involves clinical trials and real-world studies of drug treatments (such as zilucoplan, patisiran, tafamidis, and ravulizumab), evaluating their long-term safety, efficacy, and impact on patient symptoms and quality of life. This work is clinically oriented, often involving multicenter studies and collaborations to track patient outcomes over time.

Publication output has grown over the last decade, rising from single digits in earlier years to a peak of 21 in 2024, with a mean of about 12 publications per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026